title: Outcome of flat bone sarcomas (other than Ewing's) in children and adolescents: a study of 25 cases.
abstract: We analysed the clinical features and outcome of young patients with non-Ewing's flat bone sarcoma treated during the era of contemporary chemotherapy. The characteristics and outcome of 25 patients (15 males and 10 females) with primary or radiation-related flat bone sarcoma treated in the Pediatrics Department at the Institut Gustave Roussy from 1981 to 1999 were reviewed. In all, 20 patients had osteosarcoma, four chondrosarcoma and one malignant fibrous histiocytoma. The age at diagnosis ranged from 2 to 23 years (median, 15 years). Nine tumours were located in the craniofacial bones, 11 in the pelvis and five in flat bones at other sites. Four patients had metastatic disease at diagnosis. Radiation-associated flat bone osteosarcoma was diagnosed in 10 out of 25 cases. The projected overall survival and event-free survival (EFS) rates at 5 years were 45.1 and 34.3% for all the 25 patients. The EFS rate of patients with second bone sarcoma was similar to that of patients with de novo flat bone sarcoma (P=0.1). The aim of treatment was curative for 24 patients, 23 of whom were treated with intensive chemotherapy regimens and 19 with surgery. Significant adverse prognostic factors on survival included incomplete surgical resection (P=0.001) and use of regimens without pre- and postoperative chemotherapy (P=0.007). Nine of the 25 patients were treated with pre- and postoperative chemotherapy and complete surgical resection. Among them, eight are alive with no disease. Radical surgical resection is the overriding prognostic factor for flat bone sarcomas in young patients. Nevertheless, our results suggest a more favourable outcome since the advent of intensive chemotherapy.
authors.affiliation: Department of Pediatrics, Institut Gustave Roussy, 39 rue Camille Desmoulins, Villejuif Cedex 94805, France.
authors.forename: V
authors.initials: V
authors.lastname: Minard-Colin
authors.forename: C
authors.initials: C
authors.lastname: Kalifa
authors.forename: J-M
authors.initials: JM
authors.lastname: Guinebretiere
authors.forename: L
authors.initials: L
authors.lastname: Brugieres
authors.forename: J
authors.initials: J
authors.lastname: Dubousset
authors.forename: J-L
authors.initials: JL
authors.lastname: Habrand
authors.forename: G
authors.initials: G
authors.lastname: Vassal
authors.forename: O
authors.initials: O
authors.lastname: Hartmann
mesh_terms: D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D002648:Child; D002675:Child, Preschool; D002813:Chondrosarcoma / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D018219:Histiocytoma, Benign Fibrous / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D006801:Humans; D008297:Male; D009381:Neoplasms, Radiation-Induced / Q000188:drug therapy* / Q000473:pathology*; D012516:Osteosarcoma / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D011379:Prognosis; D016896:Treatment Outcome